scispace - formally typeset
Search or ask a question
Institution

Roussel Uclaf

About: Roussel Uclaf is a based out in . It is known for research contribution in the topics: Alkyl & Alkoxy group. The organization has 1888 authors who have published 2338 publications receiving 36508 citations.
Topics: Alkyl, Alkoxy group, Aryl, Carbon, Carboxylic acid


Papers
More filters
Journal ArticleDOI
O. Paulsen, L.-G. Nilsson, B. Saint-Salvi1, C. Manuel1, E. Lunell 
TL;DR: A moderate increase in dosage was needed to maintain hypocoagulability during warfarin medication, but there was no difference between the roxithromycin group and the placebo groups, respectively, and roxityromycin kinetics appeared to be unaffected by warFarin treatment.
Abstract: The macrolide antibiotics are metabolized by cytochrome P-450 enzymes in the liver and interactions with similarly metabolized compounds have been described. Simultaneous treatment with erythromycin and warfarin is known to decrease warfarin clearance and prolong prothrombin time. Roxithromycin (RU 28965), a new erythromycin derivative with improved pharmacokinetic properties, might then, because of structure similarity, be expected to interact with warfarin. In 21 healthy volunteers, the effect of orally administered roxithromycin (150 mg b.i.d.) on warfarin steady-state kinetics, and the effects of warfarin on roxithromycin kinetics, were investigated in a double-blind, randomized study versus placebo. Since the warfarin enantiomers, R- and S-warfarin have both different potency and different metabolism, the ratio between the enantiomers with and without roxithromycin, was also determined. In this study, mean AUC for warfarin increased slightly from day 14 of warfarin treatment to day 28, but no difference was found between the roxithromycin group and the placebo group, and no change appeared in the ratio between the warfarin enantiomers. A moderate increase in dosage was needed to maintain hypocoagulability during warfarin medication, but there was no difference between the roxithromycin group and the placebo groups, respectively. In addition, roxithromycin kinetics appeared to be unaffected by warfarin treatment.

27 citations

Journal ArticleDOI
TL;DR: The pharmacological profile of RU 58841 which displays a potent local antiandrogenic activity without systemic effects can be related to its very low propensity to form the N-desalkyl metabolite.

27 citations

Journal ArticleDOI
TL;DR: It is concluded that at adequate doses, RU 486 effectively blocks ovulation when administered orally in a once weekly regimen, as judged by serum LH, estradiol and progesterone levels.

27 citations

Journal ArticleDOI
TL;DR: In this paper, the steroid permeability for progesterone and a synthetic progestin was determined through films prepared from a hydrophilic acrylate-methacrylate copolymer (Eudragit R ).

26 citations

Patent
05 Jul 1991
TL;DR: In this article, the α-mercapto-alkylamines in all possible racemic, enantiomeric and diastereoisomeric forms of the formula STR1 were presented.
Abstract: Novel α-mercapto-alkylamines in all possible racemic, enantiomeric and diastereoisomeric forms of the formula ##STR1## wherein the substituents are as defined in the specification.

26 citations


Authors

Showing all 1888 results

NameH-indexPapersCitations
Fernand Labrie11088548308
Lionel H. Opie8451925964
Alain Bélanger7024416469
Michel J. Tremblay5327310485
Pierre Monsan512168049
Samir Z. Zard5057510739
Alejandro Aruffo4712314084
Samuel S.C. Yen47966865
Dominique Maraninchi471888108
Serge Erlinger461528200
Romain Lefebvre402215269
William B. Motherwell393056357
Jean-Pierre Raynaud381045075
André Lemay381144264
Patrick J. Creaven321023435
Network Information
Related Institutions (5)
Merck & Co.
48K papers, 1.9M citations

85% related

Novartis
50.5K papers, 1.9M citations

85% related

Pfizer
37.4K papers, 1.6M citations

84% related

Eli Lilly and Company
22.8K papers, 946.7K citations

84% related

AstraZeneca
23.4K papers, 938.2K citations

82% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20181
20114
20104
20091
20084
20072